Asset Acquisition, Contingent Consideration, Assumed Liabilities To Third Parties

No definition available.

Name:	txg_AssetAcquisitionContingentConsiderationAssumedLiabilitiesToThirdParties
Namespace Prefix:	txg_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Asset Acquisition, Contingent Consideration, Attributable To Sellers

+ References

No definition available.

+ Details

Name:	txg_AssetAcquisitionContingentConsiderationAttributableToSellers
Namespace Prefix:	txg_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Asset Acquisition, Contingent Consideration

+ References

No definition available.

+ Details

Name:	txg_AssetAcquisitionContingentConsiderationRollForward
Namespace Prefix:	txg_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Asset Acquisition, Gain (Loss) Contingent Consideration, Change In Fair Value Disclosure

+ References

No definition available.

+ Details

Name:	txg_AssetAcquisitionGainLossContingentConsiderationChangeInFairValueDisclosure
Namespace Prefix:	txg_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of liability recognized from contingent consideration in asset acquisition.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 15
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480123/805-50-15-3

+ Details

Name:	us-gaap_AssetAcquisitionContingentConsiderationLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	us-gaap_AssetAcquisitionAxis=txg_ScaleBioScienceInc.AcquisitionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Asset Acquisition - Contingent Consideration Liability Measured at Fair Value (Details) - USD ($) $ in Thousands		2 Months Ended	3 Months Ended	9 Months Ended
	Aug. 11, 2025	Sep. 30, 2025	Sep. 30, 2025	Sep. 30, 2025	Sep. 30, 2024
Asset Acquisition, Contingent Consideration [Roll Forward]
Change in fair value				$ 1,135	$ 0
Scale BioScience Inc. Acquisition
Asset Acquisition, Contingent Consideration [Roll Forward]
Beginning of period				0
Contingent consideration to sellers	$ 22,400			22,378
Assumed liabilities to third parties				815
Change in fair value		$ 1,100	$ 1,100	1,135
Balance at end of period		$ 24,328	$ 24,328	$ 24,328